Short Course of Intensive Lifestyle, Drug Tx Helpful in T2DM

Share this content:
Short Course of Intensive Lifestyle, Drug Tx Helpful in T2DM
Short Course of Intensive Lifestyle, Drug Tx Helpful in T2DM

THURSDAY, March 16, 2017 (HealthDay News) -- Intensive lifestyle and drug therapy is associated with achievement of normoglycemia and sustained weight loss in patients with type 2 diabetes, according to a study published online March 15 in the Journal of Clinical Endocrinology & Metabolism.

Natalia McInnes, M.D., from McMaster University in Hamilton, Canada, and colleagues randomly allocated 83 participants with type 2 diabetes to an eight-week intensive metabolic intervention, a 16-week intensive metabolic intervention, or standard diabetes care. Weight loss and normoglycemia were targeted with lifestyle approaches and treatment with metformin, acarbose, and insulin glargine during the intensive intervention period; diabetes drugs were then discontinued.

The researchers found that 50.0 and 3.6 percent of the eight-week intervention group and controls achieved normoglycemia on therapy at eight weeks (relative risk, 14.0; 95 percent confidence interval [CI], 1.97 to 99.38); these percentages were 70.4 and 3.6 percent in the 16-week and control groups, respectively, at 16 weeks (relative risk, 19.7; 95 percent CI, 2.83 to 137.13). Overall, 21.4 percent of the eight-week group and 10.7 percent of controls and 40.7 percent of the 16-week group versus 14.3 percent of controls met hemoglobin A1c criteria for complete or partial diabetes remission at 12 weeks after completion of the intervention (relative risks, 2.00 [95 percent CI, 0.55 to 7.22] and 2.85 [95 percent CI, 1.03 to 7.87], respectively).

"A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »